폐기종 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 치료별, 유통 채널별, 최종사용자별, 지역별 부문, 경쟁(2020-2030년)

Emphysema Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment, By Distribution Channel, By End-User, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,256,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,646,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,122,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

폐기종 치료 세계 시장 규모는 2024년 44억 7,000만 달러로 평가되었고, 예측 기간 동안 63억 6,000만 달러에 달할 것으로 예상되며, 2030년까지 6.02%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.

세계 폐기종 치료 시장은 의료기술의 발전과 만성 호흡기 질환에 대한 인식이 높아짐에 따라 꾸준히 성장하고 있습니다. 폐기종은 흡연 및 환경 오염 물질과 관련이 있는 진행성 폐질환으로, 유병률이 증가함에 따라 효과적인 치료 옵션에 대한 수요가 증가하고 있습니다. 제약사 및 의료기기 업체들은 지속성 기관지 확장제, 생물학적 제제, 폐활량 감소 수술(LVRS) 및 기관지 내 판막 이식술과 같은 최소 침습적 수술 등 혁신적인 치료법 개발에 적극 나서고 있습니다. 개인 맞춤형 치료 전략으로의 전환은 질병의 중증도 및 치료에 대한 개별 반응에 따라 개입을 조정함으로써 환자의 예후를 개선하고 있습니다. 휴대용 산소치료기 및 디지털 호흡 모니터링 도구와 같은 홈 헬스케어 솔루션의 확대는 질병 관리를 강화하여 시장 성장을 뒷받침하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	44억 7,000만 달러
시장 규모 : 2030년	63억 6,000만 달러
CAGR : 2025-2030년	6.02%
급성장 부문	외래수술센터
최대 시장	북미

재생의료와 유전자 기반 치료법 연구가 진행되면서 질병 변형의 가능성을 모색하는 등 치료의 전망이 바뀌고 있습니다. 표적화된 항염증 및 재생 치료제의 개발은 질병의 진행을 늦추고 폐 기능을 개선하는 것을 목표로 하고 있습니다. 바이오 제약사들은 새로운 치료 수단으로 단클론 항체와 줄기세포 요법에 주목하고 있습니다. 진단과 질병 모니터링에 인공지능(AI)을 통합하면 조기 발견과 보다 정확한 개입이 가능해져 합병증을 줄일 수 있습니다. 각 회사는 치료 효과 향상과 부작용 감소에 중점을 두고 제휴 및 임상시험을 통해 파이프라인을 확장하는 데 투자하고 있습니다. 기관지 확장제, 항염증제, 폐 재활 프로그램을 통합한 병용요법이 강조되고, 종합적인 질병 관리가 강화되고, 제품 혁신이 추진되고 있습니다.

주요 시장 성장 촉진요인

의료기술의 발전

주요 시장 이슈

높은 치료비

주요 시장 동향

최소침습 수술의 채택

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 폐기종 치료 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 치료별(금연, 기관지 확장제, 스테로이드, 류코트리엔 조절제, 산소 보급, 항생제, 유전자 치료, 수술 이식, 기타 치료)
  • 유통 채널별(병원 약국, 소매 약국, 기타 유통 채널)
  • 최종사용자별(병원 및 진료소, 외래 진료 센터, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 치료별
  • 유통 채널별
  • 최종사용자별
  • 지역별

제5장 아시아태평양의 폐기종 치료 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 치료별
  • 유통 채널별
  • 최종사용자별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 폐기종 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 폐기종 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 멕시코
  • 캐나다

제8장 남미의 폐기종 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 폐기종 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트(UAE)

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제12장 세계의 폐기종 치료 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Icure Pharmaceuticals Inc.
• AstraZeneca Plc.
• Teva Pharmaceuticals Industries Ltd.
• Novartis AG
• GlaxoSmithKline Plc.
• Hikma Pharmaceuticals Plc
• Boehringer Ingelheim International GmbH
• Mylan N.V.
• Pfizer Inc.
• Orion Corporation

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Emphysema Treatment Market was valued at USD 4.47 Billion in 2024 and is expected to reach USD 6.36 Billion in the forecast period with a CAGR of 6.02% through 2030. The global emphysema treatment market is witnessing steady growth, driven by advancements in medical technology and increasing awareness about chronic respiratory diseases. Emphysema, a progressive lung condition often linked to smoking and environmental pollutants, has seen a rise in prevalence, prompting demand for effective treatment options. Pharmaceutical and medical device companies are actively developing innovative therapies, including long-acting bronchodilators, biologics, and minimally invasive procedures like lung volume reduction surgery (LVRS) and endobronchial valve implantation. The shift toward personalized treatment strategies is improving patient outcomes by tailoring interventions based on disease severity and individual response to therapy. The expansion of home healthcare solutions, including portable oxygen therapy devices and digital respiratory monitoring tools, is enhancing disease management and supporting market growth.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 4.47 Billion
Market Size 2030	USD 6.36 Billion
CAGR 2025-2030	6.02%
Fastest Growing Segment	Ambulatory Surgical Centers
Largest Market	North America

Ongoing research into regenerative medicine and gene-based therapies is transforming the treatment landscape by exploring potential disease-modifying solutions. The development of targeted anti-inflammatory and regenerative therapies aims to slow disease progression and improve lung function. Biopharmaceutical companies are focusing on monoclonal antibodies and stem cell therapies as emerging treatment avenues. The integration of artificial intelligence (AI) in diagnostics and disease monitoring is enabling early detection and more precise intervention, reducing complications. Companies are investing in pipeline expansion through collaborations and clinical trials, with an emphasis on improving treatment efficacy and reducing adverse effects. The emphasis on combination therapies, incorporating bronchodilators, anti-inflammatory drugs, and pulmonary rehabilitation programs, is enhancing comprehensive disease management and driving product innovation.

Key Market Drivers

Advancements in Medical Technology

Advancements in medical technology are significantly enhancing the global emphysema treatment market. Emphysema, a debilitating form of chronic obstructive pulmonary disease (COPD), has historically been challenging to manage. However, recent technological breakthroughs are transforming emphysema care.

Minimally invasive procedures, such as bronchoscopic lung volume reduction (BLVR), have become pivotal in emphysema treatment. BLVR involves the insertion of devices like endobronchial valves to occlude diseased lung regions, thereby improving respiratory function. Clinical studies have demonstrated that BLVR can enhance lung performance and quality of life in selected patients. For instance, research indicates that BLVR procedures have shown promising outcomes in improving lung function and exercise capacity among patients with advanced emphysema.

The development of biologics and targeted therapies marks another significant advancement in emphysema management. These treatments aim at specific molecular pathways that contribute to disease progression, potentially decelerating emphysema's advancement and enhancing pulmonary function. This targeted approach offers a more effective and less invasive alternative to traditional therapies.

Key Market Challenges

High Treatment Costs

High treatment costs are a significant barrier hindering the advancement of the Global Emphysema Treatment Market. Emphysema, a debilitating chronic obstructive pulmonary disease (COPD), affects millions of individuals worldwide, and managing this condition can be financially burdensome for both patients and healthcare systems.

The development of innovative emphysema treatments, such as bronchoscopic lung volume reduction (BLVR) procedures and targeted biologics, has offered new hope to patients by providing potentially more effective and less invasive options. However, these cutting-edge treatments often come with a hefty price tag.

For many emphysema patients, the high cost of treatment represents a substantial financial barrier. Coping with the financial burden of these therapies can be overwhelming, particularly for those without comprehensive health insurance coverage. High deductibles, copayments, and out-of-pocket expenses can strain patients' finances and limit their access to essential treatments.

Additionally, emphysema is a chronic condition that often requires ongoing care, including medications, regular check-ups, and pulmonary rehabilitation. These long-term expenses further compound the financial challenges faced by patients, potentially forcing them to make difficult choices between healthcare and other essential needs.

The burden of high treatment costs also extends to healthcare systems and governments. As the prevalence of emphysema continues to rise, the strain on healthcare budgets becomes more pronounced. The cost of providing advanced treatments and therapies can lead to allocation challenges, diverting resources from other critical healthcare needs.

Key Market Trends

Adoption of Minimally Invasive Procedures

The adoption of minimally invasive procedures is playing a pivotal role in boosting the Global Emphysema Treatment Market. Emphysema, a progressive lung condition characterized by the destruction of lung tissue, has traditionally been associated with invasive surgical treatments or long-term medication. However, recent advancements in medical technology have led to the development and widespread adoption of minimally invasive procedures, offering a paradigm shift in the way emphysema is treated.

One of the most significant contributors to the growth of minimally invasive procedures is the emergence of bronchoscopic lung volume reduction (BLVR) techniques. BLVR involves the insertion of small devices or materials into the airways to block or reduce airflow to damaged lung areas. This procedure aims to improve lung function and alleviate symptoms without the need for open surgery. Patients benefit from shorter hospital stays, faster recovery times, and reduced risk of complications compared to traditional surgical approaches.

The appeal of minimally invasive procedures goes beyond their effectiveness; it lies in their patient-centric approach. Patients are more inclined to opt for less invasive treatments that offer quicker recovery times and a lower risk of complications. As a result, healthcare providers increasingly recommend and perform BLVR and other minimally invasive procedures, meeting the preferences and expectations of patients.

Moreover, the adoption of minimally invasive procedures aligns with the broader trend in healthcare toward value-based care and cost-effectiveness. These procedures typically lead to reduced healthcare costs due to shorter hospital stays and less post-operative care, benefiting both patients and healthcare systems.

Key Market Players

• Icure Pharmaceuticals Inc.
• AstraZeneca Plc.
• Teva Pharmaceuticals Industries Ltd.
• Novartis AG
• GlaxoSmithKline Plc.
• Hikma Pharmaceuticals Plc
• Boehringer Ingelheim International GmbH
• Mylan N.V.
• Pfizer Inc.
• Orion Corporation

Report Scope:

In this report, the Global Emphysema Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Emphysema Treatment Market, By Treatment:

• Smoking Cessation
• Bronchodilators
• Steroids
• Leukotriene Modifiers
• Supplemental Oxygen
• Antibiotics
• Gene Therapy
• Surgery Transplant
• Other Treatments

Emphysema Treatment Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels

Emphysema Treatment Market, By End-User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Emphysema Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Emphysema Treatment Market.

Available Customizations:

Global Emphysema Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Emphysema Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment (Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments)
  • 4.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
  • 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Treatment
  • 4.3.2. By Distribution Channel
  • 4.3.3. By End-User
  • 4.3.4. By Region

5. Asia Pacific Emphysema Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment
  • 5.2.2. By Distribution Channel
  • 5.2.3. By End-User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Emphysema Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment
      • 5.3.1.2.2. By Distribution Channel
      • 5.3.1.2.3. By End-User
  • 5.3.2. India Emphysema Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment
      • 5.3.2.2.2. By Distribution Channel
      • 5.3.2.2.3. By End-User
  • 5.3.3. Australia Emphysema Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment
      • 5.3.3.2.2. By Distribution Channel
      • 5.3.3.2.3. By End-User
  • 5.3.4. Japan Emphysema Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment
      • 5.3.4.2.2. By Distribution Channel
      • 5.3.4.2.3. By End-User
  • 5.3.5. South Korea Emphysema Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment
      • 5.3.5.2.2. By Distribution Channel
      • 5.3.5.2.3. By End-User

6. Europe Emphysema Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Distribution Channel
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Emphysema Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Distribution Channel
      • 6.3.1.2.3. By End-User
  • 6.3.2. Germany Emphysema Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Distribution Channel
      • 6.3.2.2.3. By End-User
  • 6.3.3. Spain Emphysema Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Distribution Channel
      • 6.3.3.2.3. By End-User
  • 6.3.4. Italy Emphysema Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment
      • 6.3.4.2.2. By Distribution Channel
      • 6.3.4.2.3. By End-User
  • 6.3.5. United Kingdom Emphysema Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment
      • 6.3.5.2.2. By Distribution Channel
      • 6.3.5.2.3. By End-User

7. North America Emphysema Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Distribution Channel
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Emphysema Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Distribution Channel
      • 7.3.1.2.3. By End-User
  • 7.3.2. Mexico Emphysema Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Distribution Channel
      • 7.3.2.2.3. By End-User
  • 7.3.3. Canada Emphysema Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Distribution Channel
      • 7.3.3.2.3. By End-User

8. South America Emphysema Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Distribution Channel
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Emphysema Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Distribution Channel
      • 8.3.1.2.3. By End-User
  • 8.3.2. Argentina Emphysema Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Distribution Channel
      • 8.3.2.2.3. By End-User
  • 8.3.3. Colombia Emphysema Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Distribution Channel
      • 8.3.3.2.3. By End-User

9. Middle East and Africa Emphysema Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Distribution Channel
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Emphysema Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Distribution Channel
      • 9.3.1.2.3. By End-User
  • 9.3.2. Saudi Arabia Emphysema Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Distribution Channel
      • 9.3.2.2.3. By End-User
  • 9.3.3. UAE Emphysema Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Distribution Channel
      • 9.3.3.2.3. By End-User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Emphysema Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Icure Pharmaceuticals Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. AstraZeneca Plc.
• 14.3. Teva Pharmaceuticals Industries Ltd.
• 14.4. Novartis AG
• 14.5. GlaxoSmithKline Plc.
• 14.6. Hikma Pharmaceuticals Plc
• 14.7. Boehringer Ingelheim International GmbH
• 14.8. Mylan N.V.
• 14.9. Pfizer Inc.
• 14.10. Orion Corporation

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료